Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Jun;50(6):2210-3.
doi: 10.1128/AAC.01447-05.

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen

Florence Doualla-Bell  1 , Ava Avalos, Tendani Gaolathe, Madisa Mine, Simani Gaseitsiwe, Ndwapi Ndwapi, Vladimir A Novitsky, Bluma Brenner, Maureen Oliveira, Daniella Moisi, Howard Moffat, Ibou Thior, Max Essex, Mark A Wainberg
Affiliations
Comparative Study

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen

Florence Doualla-Bell et al. Antimicrob Agents Chemother. 2006 Jun.

Abstract

Among 16 human immunodeficiency virus-infected (subtype C) Batswana patients who failed nelfinavir (NFV)-containing regimens, the most prevalent mutation observed was D30N (54%), followed by L90M (31%). L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Prevalence of HIV-1 subtype C protease mutations and polymorphisms in Batswana patients receiving nelfinavir. Comparison with HIV-1 subtype C Stanford database. Polymorphisms and mutation frequencies at amino acid positions 1 to 99 of PR sequences from Batswana (A) and SDB (B) HIV-1 subtype C-infected patients. (A) Sequences from the 51 Batswana patients at baseline (black bars) and the 13 Batswana patients presenting primary mutations associated with NFV resistance (white bars) (B) SDB sequences pretherapy (black bars) and SDB sequences from 31 to 66 NFV-treated patients (white bars). Statistical significance was determined by Fisher's two-tailed exact test. *, P < 0.001; **, P < 0.05.
See this image and copyright information in PMC

References

    1. Brenner, B., D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5. - PubMed
    1. Diallo, K., B. Brenner, M. Oliveira, D. Moisi, M. Detorio, M. Gotte, and M. A. Wainberg. 2003. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob. Agents Chemother. 47:2376-2379. - PMC - PubMed
    1. Doualla-Bell, F., A. Avalos, T. Gaolathe, M. Mine, S. Gaseitsiwe, B. Brenner, N. Ndwapi, H. Moffat, I. Thior, M. Essex, and M. A. Wainberg. 2005. Frequency and patterns of specific PR mutations in Batswana subtype C patients who failed a nelfinavir-containing HAART regimen. XIV International HIV Drug Resistance Workshop, June 7-11, 2005. Antivir. Ther. 10:S150.
    1. Doualla-Bell, F., S. Gaseitsiwe, T. Ndungu, M. Modukanele, T. Peter, V. A. Novitsky, N. Ndwapi, G. Tendani, A. Avalos, W. Wester, H. Bussmann, P. Cardiello, R. Marlink, H. Moffat, I. Thior, M. A. Wainberg, and M. Essex. 2004. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir. Chem. Chemother. 15:189-200. - PubMed
    1. Frater, J. 2002. The impact of HIV-1 subtype on the clinical response on HAART. J. HIV Ther. 7:92-96. - PubMed

Publication types

MeSH terms